70.3 🩺 內科專科考前版

70.3.0.1 📌 䞀頁重點

  • 22E: PET-CT widely used, novel lymphoma therapies (CAR-T, BiTE)
  • Taiwan: TB / EBV / hep / lymphoma incidence

70.3.0.2 🌟 Pearls (8)

  1. PET-CT (Deauville) lymphoma staging + response
  2. CAR-T: tisagenlecleucel, axicabtagene for R/R DLBCL
  3. Bispecific Ab (BiTE): blinatumomab (CD19), mosunetuzumab, glofitamab
  4. Castleman disease: HHV-8, IL-6 → siltuximab
  5. Rosai-Dorfman: SHP/cyclophosphamide for symptomatic
  6. Kikuchi-Fujimoto disease: 亞掲青幎女性 + self-limited
  7. MALT lymphoma + H. pylori: eradication may regress
  8. Non-PCP lymphocytopenia: HIV, idiopathic CD4 lymphopenia

70.3.0.3 📍 Taiwan

  • TB endemic → scrofula
  • HBV/HCV → 肝盞關 LAP
  • EBV-related lymphoma 范高
  • 健保 PET-CT for lymphoma staging
  • 健保 CAR-T 限制

70.3.0.4 🎓 內專重點

  1. CHICAGO + biopsy decision
  2. Lymphoma subtypes
  3. CLL flow + treatment
  4. CAR-T + BiTE (22E)
  5. Splenectomy vaccine
  6. Kikuchi / Castleman / Rosai-Dorfman

⚠ AI 草皿。